- Trials with a EudraCT protocol (22)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
22 result(s) found for: Sinus arrhythmia.
Displaying page 1 of 2.
EudraCT Number: 2008-001201-42 | Sponsor Protocol Number: 4-001-LVS | Start Date*: 2008-06-01 | |||||||||||
Sponsor Name:POLICLINICO SAN DONATO IRCSS | |||||||||||||
Full Title: Clinical trial on the use of ivabradine in patients with inappropriate sinus tachycardia | |||||||||||||
Medical condition: Inappropriate sinus tachycardia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001716-59 | Sponsor Protocol Number: D4120C00002 | Start Date*: 2011-10-14 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Phase II Study to Assess the Effects on Atrial and Ventricular Refractoriness of an Intravenous Infusion of AZD2927 in Patients Undergoi... | |||||||||||||
Medical condition: Arrhythmia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014940-12 | Sponsor Protocol Number: CL2-44121-006 | Start Date*: 2010-03-11 | |||||||||||||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||||||||||||
Full Title: Evaluation of the anti-arrhythmic effects of 3 oral dosages of S 44121 versus placebo in patients with chronic heart failure and left ventricular systolic dysfunction at risk for ventricular arrhyt... | |||||||||||||||||||||||
Medical condition: Chronic Heart Failure and left ventricular systolic dysfunction at risk for ventricular arrhythmia | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) HU (Completed) SK (Completed) ES (Completed) PT (Completed) GB (Completed) CZ (Completed) DE (Completed) BE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-004433-24 | Sponsor Protocol Number: 59498 | Start Date*: 2017-05-17 |
Sponsor Name:Leids Universitair Medisch Centrum | ||
Full Title: ACE inhibition in Fontan patients: its effect on body fluid regulation. | ||
Medical condition: Patients with univentricular hearts palliated by the Fontan procedure | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-004865-11 | Sponsor Protocol Number: IV-FLEC | Start Date*: 2022-03-21 |
Sponsor Name:Win Medica Pharmaceuticals S.A. | ||
Full Title: Comparison of the effectiveness of IntraVenous FLECainide plus oral ranolazine versus intravenous flecainide alone in the cardioversion of recent onset atrial fibrillation – a randomized, prospecti... | ||
Medical condition: Restoration of sinus rhythm in patients with recent AF onset | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000833-38 | Sponsor Protocol Number: ISIS329993-CS6 | Start Date*: 2012-06-19 | |||||||||||
Sponsor Name:Isis Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2 Study to Assess the Antiarrhythmic and Symptomatic Effect of the Second Generation Antisense Oligonucleotide ISIS 329993 Targeting CRP in Patients with Paroxysmal Atrial Fibrillation | |||||||||||||
Medical condition: Atrial fibrillation (AF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000984-81 | Sponsor Protocol Number: 04-7-010 | Start Date*: 2004-09-09 | |||||||||||
Sponsor Name:Astellas Pharma US, Inc. | |||||||||||||
Full Title: A PHASE III PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, TOLERANCE AND EFFICACY STUDY OF RSD1235 IN SUBJECTS WITH ATRIAL FIBRILLATION OR ATRIAL FLUTTER | |||||||||||||
Medical condition: Arrhythmias are abnormal rhythms of the heart. The term arrhythmia refers to a deviation from the normal sequence of initiation and conduction of electrical impulses, which cause the heart to beat.... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004195-20 | Sponsor Protocol Number: 05-7-012 | Start Date*: 2005-12-12 | |||||||||||
Sponsor Name:Astellas Pharma US, Inc. | |||||||||||||
Full Title: A Phase 3, Multi-Center, Open Label Safety Study of RSD1235 in Subjects with Atrial Fibrillation. | |||||||||||||
Medical condition: Arrhythmias are abnormal rhythms of the heart. The term arrhythmia refers to a deviation from the normal sequence of initiation and conduction of electrical impulses, which cause the heart to beat... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003492-35 | Sponsor Protocol Number: MED2-201301 | Start Date*: 2015-05-26 |
Sponsor Name:University of Bonn | ||
Full Title: Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation with Dabigatran after Pulmonary Vein Isolation for Atrial Fibrillation | ||
Medical condition: atrial fibriallation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2011-002789-18 | Sponsor Protocol Number: RAF-01 | Start Date*: 2011-11-15 | |||||||||||
Sponsor Name:Menarini Ricerche S.p.A | |||||||||||||
Full Title: A RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING PHASE II STUDY ASSESSING RANOLAZINE IN THE MAINTENANCE OF SINUS RHYTHM AFTER ELECTRICAL CARDIOVERSION IN PATIENTS WITH NON... | |||||||||||||
Medical condition: NON-PERMANENT ATRIAL FIBRILLATION | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000187-15 | Sponsor Protocol Number: MK-8616-145 | Start Date*: 2017-09-18 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or Vecu... | |||||||||||||
Medical condition: Reversal of neuromuscular blockade | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002541-11 | Sponsor Protocol Number: P170912J | Start Date*: 2019-06-06 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Prevention of post-operative Atrial Fibrillation by BOTulinum toxin injections into epicardial fat pads around pulmonary veins in patients undergoing cardiac surgery | |||||||||||||
Medical condition: Adult patients with indication for conventional cardiac surgery (CABG, aortic replacement, or ascending aorta surgery) will be eligible | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001507-76 | Sponsor Protocol Number: BRONCHIOLE2017 | Start Date*: 2017-09-20 |
Sponsor Name:Region Örebro län | ||
Full Title: Beta-blockeRs tO patieNts with CHronIc Obstructive puLmonary diseasE (BRONCHIOLE) A pragmatic clinical trial with partial registry-based follow-up | ||
Medical condition: Chronic Obstructive Pulmonary disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-006614-37 | Sponsor Protocol Number: CryoStopPersAF | Start Date*: 2022-05-11 | |||||||||||
Sponsor Name:Region Örebro | |||||||||||||
Full Title: First-line cryoablation for early treatment of Persistent Atrial Fibrillation – a randomized study comparing early trigger isolation using the Cryoballoon versus antiarrhythmic medication. | |||||||||||||
Medical condition: Persistent symptomatic atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017582-29 | Sponsor Protocol Number: OPERA-AF | Start Date*: 2010-03-01 | |||||||||||
Sponsor Name:CONSORZIO MARIO NEGRI SUD | |||||||||||||
Full Title: Omega-3 fatty acids for Prevention of post-opERative Atrial fibrillation (OPERA) | |||||||||||||
Medical condition: Patients scheduled for cardiac surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022947-39 | Sponsor Protocol Number: CV203-010 | Start Date*: 2011-03-18 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: Randomized, Double-Blind, Placebo-Controlled, 4-Way Crossover Study to Evaluate the Safety, Tolerability and Effect on Atrial Fibrillation Burden of BMS-914392 in Patients with Paroxysmal Atrial Fi... | ||||||||||||||||||
Medical condition: Atrial Fibrillation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-017838-44 | Sponsor Protocol Number: CJO-201 | Start Date*: 2010-04-21 | |||||||||||
Sponsor Name:Sequel Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Pilot Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Centered Safety, Tolerability and Preliminary Efficacy Study of K201 Oral for the Prevention of Atrial Fibrillation (AF) Recurre... | |||||||||||||
Medical condition: Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001853-89 | Sponsor Protocol Number: CLI-043 | Start Date*: 2006-07-07 |
Sponsor Name:Vion Pharmaceuticals, Inc | ||
Full Title: A phase II study of Cloretazine for elderly patients with de novo poor risk acute myelogenous leukemia. | ||
Medical condition: Acute Myelogenous Leukemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-005625-29 | Sponsor Protocol Number: VERI-305-AMIO | Start Date*: 2008-03-06 | |||||||||||
Sponsor Name:Cardiome Pharma Corp. | |||||||||||||
Full Title: A Phase III Prospective, Randomized, Double-Blind, Active-Controlled, Multi-Center, Superiority Study of Vernakalant Injection versus Amiodarone in Subjects with Recent Onset Atrial Fibrillation | |||||||||||||
Medical condition: Treatment of Atrial fibrillation (AF). AF is the most common arrhythmia encountered in clinical practice. It is usually associated with age and general physical condition, rather than with a speci... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) FR (Completed) LT (Completed) EE (Completed) DK (Completed) CZ (Completed) FI (Completed) SK (Completed) LV (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001200-38 | Sponsor Protocol Number: OTIS2019_001 | Start Date*: 2020-11-17 | |||||||||||
Sponsor Name:Karolinska Universitetssjukhuset | |||||||||||||
Full Title: Octreotide treatment to improve nutritional recovery after surgery for patients with esophageal or gastric cancer, a prospective randomized open label phase II study - OTIS | |||||||||||||
Medical condition: Undesired weight loss after operation for esophageal or gastric cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
